Company news
Marker Therapeutics, Inc. (NASDAQ:MRKR) news
Marker Therapeutics, Inc. news releases on 6ix. Latest, Sep 13, 2022: Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2…
Press releases — page 2
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
September 12, 2022
Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference
September 7, 2022
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
August 10, 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
August 3, 2022
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
May 12, 2022
Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting
May 3, 2022
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
April 25, 2022
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
March 16, 2022
Marker Therapeutics to Present at Two Upcoming March Investor Conferences
March 6, 2022
Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion
February 15, 2022
Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022
February 7, 2022
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer
January 18, 2022
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
December 8, 2021
Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
November 17, 2021
Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results
November 9, 2021
Marker Therapeutics to Present at Three Upcoming September Investor Conferences
September 6, 2021
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
August 18, 2021
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
August 9, 2021
Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility
July 27, 2021
Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML
July 5, 2021
Marker Therapeutics to Present at the Virtual Raymond James Human Health Innovation Conference
June 15, 2021
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
May 11, 2021
Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021
April 28, 2021
Marker Therapeutics to Present Multi-Tumor-Associated Antigen (mTAA)-Specific T Cell Manufacturing Robotics Data at the 2021 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
April 26, 2021
Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock
March 15, 2021
Marker Therapeutics to Present at the Virtual Oppenheimer 31st Annual Healthcare Conference
March 14, 2021
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
March 11, 2021
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
March 10, 2021
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
March 8, 2021
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant
March 2, 2021
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
January 12, 2021
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial
January 4, 2021
Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results
November 8, 2020
Marker Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, November 9, 2020
November 1, 2020
Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 16, 2020
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results
August 9, 2020
Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
June 29, 2020
Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia
June 22, 2020
Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
May 28, 2020
Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting
May 12, 2020
Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results
May 10, 2020
Marker Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast on Monday, May 11, 2020
May 3, 2020
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
April 28, 2020
Marker Therapeutics Reports Full Year 2019 Operating and Financial Results
March 11, 2020
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
March 1, 2020
Marker Therapeutics to Present at Two Upcoming Investor Conferences
February 17, 2020
Marker Therapeutics Announces Update to its Clinical Program in AML
February 10, 2020
Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results
November 11, 2019
Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019
November 10, 2019
Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs
August 14, 2019